Site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

Establish Treatment expectations and goals

Setting HAE treatment expectations

HAE is a genetic, unpredictable, and lifelong condition, and it's important to set specific goals for therapy.1

Choosing effective prevention with TAKHZYRO means working together with your patients to help prevent and reduce the severity of their HAE attacks—which may align with their treatment goals.1

Create a regular check-in schedule to review progress and treatment goals—as routine monitoring is recommended by the 2020 HAEA guidelines.1


Cultivating Lifelong Relationships

HCPs can play a big role in keeping patients engaged throughout their entire treatment journey: discussing positive outcomes, working through breakthrough attacks, celebrating milestones, staying committed, and more. Watch as a real TAKHZYRO patient speaks with an HAE expert about all the ways they can stay connected throughout their treatment journey.

View Transcript

Dr William Lumry: ... exactly.

Pam: You never know what you're going to be doing. Oh, hi.

Dr William Lumry: Thank you, Kevin.

Pam: It looks great, thank you.

Dr William Lumry: Appreciate it. Pam, it's great to see you. The last time we talked, you were planning a family party, I think, right?

Pam: We did. Everyone had a great time and I wasn't worried about experiencing an HAE attack.

Dr William Lumry: That's great to hear. I remember you sharing stories about avoiding certain events because of concern about having an attack, and how the unpredictability of attacks impacted you.

Pam: I think those conversations really helped you understand what I was going through and helped me get on the right preventive treatment.

Dr William Lumry: I've heard from many of my patients that preventive therapy has helped them. I'm glad it's worked that way for you. How are your daughters doing?

Pam: They're wonderful. One just came back from a trip abroad. Thanks for preparing us in case she had an attack while she was gone.

Dr William Lumry: Of course, I'm always happy to help patients plan ahead to reduce the possibility of an HAE attack.

Pam: Well, thanks to you, the timing worked out, so she was between doses during her vacation and she didn't need to pack her preventive medication, so she had a really great time.

Dr William Lumry: Good for her.

Pam: I'm just so grateful that my girls and I have someone like you who's been a part of our lives for over 10 years and who really knows us and understands what we're going through with our HAE.

Dr William Lumry: That's why we do what we do. You know, I'm glad I was able to prescribe the three of you TAKHZYRO and that it's been effective for you. You know, HAE attacks affect every patient differently, so each patient needs to be treated uniquely. When I talk about treatment options, we discuss their expectations regarding efficacy, preferences for the route of administration, potential side effects, safety information, the approval process, and so on and so on. That helps them decide which treatment might be best for them.

Pam: There is a lot to consider.

Dr William Lumry: There really is. And on top of that, as you know, HAE can change over time. It can become more or less severe, as a result, a patient's needs may change too, so healthcare providers need to keep checking in and continuing to ask the right questions.

Pam: You were the first physician, after years of searching, who listened to me instead of just talking to me, and you asked how I was really feeling, what was going on in my life, what I wanted to accomplish, how my HAE affected me, and how I felt between attacks.

Dr William Lumry: And to your credit, you answered all the questions. You know, not all patients are comfortable talking about their lives in that way, but it helps paint a fuller picture so together we can figure out the best way to manage their HAE attacks.

Pam: It's been a long journey for me to feel like my HAE doesn't define me.

Dr William Lumry: And that journey you talk about is ongoing, Pam. It doesn't end once you're on a preventive treatment you're happy with. We discuss updates on how you're feeling, if anything has changed with your HAE, and if the treatment is still meeting your goals.

Pam: I can't begin to tell you how much that means to me and my family.

Dr William Lumry: I want my patients to be engaged every step of the way and empowered to feel like they have choices, and I want them to trust that our office will be true partners with them throughout their journey.

Pam: I totally feel that and I know my daughters do too.

Dr William Lumry: That's great. And TAKHZYRO offers patients every-two-week dosing with the option of going to every four weeks if things are well controlled, which I hope has helped as well.

Pam: TAKHZYRO has made a difference in our lives by reducing HAE attacks. I have to tell you, I'm so relieved that there's something available that has been proven to help reduce the frequency of those attacks.

Dr William Lumry: I am too, and I appreciate how you keep me informed about your progress, not just with TAKHZYRO, but with everything going on in your life. It helps us make sure we can keep up with your routine.

Pam: Well, you've made yourself so available to me and my family over the years, and you've gone above and beyond to take care of us. Thank you for everything that you continue to do for those of us with HAE.

Dr William Lumry: Thank you, Pam. I'm glad we got a chance to visit today.

Narrator: TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.
Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10%) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; dizziness; diarrhea; and myalgia. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <2 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-877-TAKEDA-7 (1-877-825-3327), or FDA at 1-800-FDA-1088 or

Please see full Prescribing Information at


Give TAKHZYRO 2.5 months to reach steady state (for patients age 12 and older)2,3

Graph indicating that steady state with TAKHZYRO® occurs after about 70 days.

Encourage your patients to keep taking TAKHZYRO exactly as you prescribed. TAKHZYRO has a half-life of ~14 days, allowing it to be taken every 2 weeks. Because of this, it can take up to 6 doses (10 weeks) to reach steady state.2,3

Challenge your patient to make a commitment to themselves and TAKHZYRO
Take each dose as prescribed

TAKHZYRO continues to work as it is taken, so it is important to tell your patients to take each dose as prescribed. Remember to impress upon them to avoid skipping or missing doses.2

Breakthrough attacks

It is normal for patients to experience breakthrough attacks.2

It is recommended that patients keep their acute medication on hand in case of a breakthrough attack.1

Let your patient know that if a breakthrough attack happens, they should not be discouraged. They should keep taking TAKHZYRO as prescribed and discuss their experience with you.2

Stay the course

Over time, your patient may begin to notice that their attacks are less severe or that they are using their on-demand treatment less. These are signs that TAKHZYRO is working.

Long-term prevention.
Long-term support.

Find suggestions for helping your patients stay on top of preventing HAE attacks with TAKHZYRO.

Keep patients on track

HCP and patient resources

Find materials and forms to help get patients started on TAKHZYRO.

See resources

References: 1. Busse PJ, Christiansen SC, Riedl MA, et al. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046 2. Takhzyro. Prescribing information. Dyax Corp; 2023. 3. Wang Y, Marier JF, Kassir N, Chang C, Martin P. Clin Transl Sci. 2020:13(6):1208-1216. doi: 10.1111/cts.12806 4. Banerji A, Bernstein JA, Johnston DT, et al; HELP OLE Investigators. Allergy. 2022;77(3):979-990. do:10.1111/all.15011 5. Cinryze. Prescribing information. Takeda Pharmaceuticals USA, Inc; 2023. 6. Haegarda. Prescribing information. CSL Behring LLC; 2022. 7. Orladeyo. Prescribing information. BioCryst Pharmaceuticals, Inc: 2022.